Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …

Since its FDA approval, chimeric antigen receptor (CAR)-T cell therapy is changing the
landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and …

Multiple Myeloma remains incurable, and there is a need for therapies with novel
mechanisms of action. Recently, B cell maturation antigen targeted therapy has …

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR
T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the …

Chimeric antigen receptor T‐cell (CAR‐T) therapy targeting B‐cell maturation antigen
(BCMA) has shown profound efficacy and manageable toxicity in patients with …

Despite continued advances that have led to improved survival of patients with multiple
myeloma (MM) over the years, MM remains largely incurable with overall survival in patients …

Simple Summary In newly diagnosed multiple myeloma patients (NDMM) the introduction of
three-drug, and recently, four-drug combinations allowed to reach response rates never …

Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment
of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell …

B-cell maturation antigen (BCMA)–directed therapies, including antibody-drug conjugates,
bispecific antibodies (BsAbs), and chimeric antigen receptor T cells (CARTs), have shown …

Over the past few decades, the landscape for multiple myeloma (MM) therapy has
significantly advanced, largely due to the approval and introduction of new-generation …